 |
 |
|
| Startseite |
| Impressum |
| Datenschutz |
 |
| SPOT ON | |
Jupiter study: no expansion of indication for statins | |
| NEW ON THE MARKET | |
Rifaximin (XIFAXAN) for traveler`s diarrhea? | |
| THERAPY FROM A CRITICAL VIEWPOINT | |
Prevention with antioxidants: damage outweighs benefit | |
| a-t READERS' QUESTIONS AND COMMENTS | |
Aspirin (ASS) for primary prevention in all diabetics? | |
| IN BRIEF | |
More agents against head lice tested by the German Federal Environmental Agency | |
 |
Scientists criticize HPV-vaccination |
| CURRENT ADR NETWORK REPORT | |
CNS-damage due to strontium ranelate (PROTELOS) | |
| SIDE EFFECTS | |
Efalizumab (RAPTIVA): progressive multifocal leukoencephalopathy (PML) | |
|
© arznei-telegramm 12/2008 | ||
 |  | |